Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (39)

2024

  1. An algorithm for the diagnosis of betalactam allergy, 2024 update

    Allergy: European Journal of Allergy and Clinical Immunology

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  2. Management of patients with suspected or confirmed antibiotic allergy. Executive summary of guidance from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Allergy and Clinical Immunology (SEAIC), the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Intensive Medicine and Coronary Care Units (SEMICYUC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 181-186

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  3. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

    Blood cancer journal, Vol. 12, Núm. 2, pp. 32

  4. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  5. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

  6. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  2. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  3. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2020

  1. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 34, Núm. 8, pp. 2000-2011

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

  2. Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)

    Leukemia

  3. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers

    Journal of Immunological Methods, Vol. 475

  4. Insights on Multiple Myeloma Treatment Strategies

    HemaSphere, Vol. 3, Núm. 1

  5. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

    Blood Cancer Journal, Vol. 9, Núm. 4

2018

  1. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    Leukemia, Vol. 32, Núm. 11, pp. 2427-2434

2016

  1. Allergic rhinitis causes loss of smell in children: The OLFAPEDRIAL study

    Pediatric Allergy and Immunology, Vol. 27, Núm. 8, pp. 867-870